Nasdaq · Healthcare
Entrada Therapeutics, Inc. (TRDA)
As-reported financials and recent SEC filings for Entrada Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$25.4M
Net income
$-143.8M
Net margin
—
Diluted EPS
$-3.47
ROE
-47.0%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $25.4M | $210.8M | $129.0M | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-157.9M | $47.0M | $-3.2M | $-97.2M | $-51.1M |
| Net income | $-143.8M | $65.6M | $-6.7M | $-94.6M | $-51.2M |
| Diluted EPS | $-3.47 | $1.68 | $-0.20 | $-3.02 | $-1.63 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →8-K2026-06-10
View on EDGAR →42026-05-21
View on EDGAR →Largest Healthcare peers
Go deeper on TRDA
Search Entrada Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.